Human HDAC6 with H216A mutation (GenBank Accession No. NM_006044), full length with N-terminal GST-tag, MW= 161 kDa, expressed in a baculovirus expression system.

Q9UBN7

histone deacetylase 6, HDAC6

≥380 pmol/min/µg

25 mM Tris/HCl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl₂, and 0.1 mg/ml BSA, 20 µM BPS HDAC substrate 3 (Catalog #50037), and HDAC6 H216A (1.6 - 100 ng). Incubation condition: 30 min at 37°C followed by HDAC developer (Catalog #50030) for 15 min at room temperature. Fluorescence intensity is measured at ex360/em460.

50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 50 mM KCl, 2 mM EDTA, 10% glycerol, and 2 mM DTT

Protein was purified by affinity chromatography and gel filtration.

Aqueous buffer solution

>6 months at -80°C.

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

1. Li S. et al., Neurology. 41(2), 112-6 (2010).
2. Strausberg, R.L. et al., Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002).

Application References:
1. Kinetic method for the large-scale analysis of the binding mechanism of histone deacetylase inhibitors (2014)
2. Potent histone deacetylase inhibitors derived from 4-(aminomethyl)-N-hydroxybenzamide with high selectivity for the HDAC6 isoform (2013)
3. Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp (2013)
4. Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors (2013)

Avoid freeze/thaw cycles.

Deacetylase

Recombinant Protein